CD19 and B-cell chronic lymphocytic leukemia: However, the ORR in patients with CLL treated with anti-CD19 CAR-T cells is substantially lower at about 30% [75], indicating that targeting the same antigen in different malignancies results in heterogeneous therapy responses probably due to the unique nature and microenvironment of different tumor types.